Anti-TNF alpha Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373813" target="_blank" >RIV/00216208:11130/17:10373813 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373813

Výsledek na webu

<a href="https://doi.org/10.1097/MIB.0000000000001050" target="_blank" >https://doi.org/10.1097/MIB.0000000000001050</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MIB.0000000000001050" target="_blank" >10.1097/MIB.0000000000001050</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Anti-TNF alpha Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

Popis výsledku v původním jazyce

Background: The outcome of patients with Crohn&apos;s disease who failed anti-tumor necrosis factor alpha (anti-TNF alpha) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNF alpha agent postoperatively. Methods: Pediatric patients with Crohn&apos;s disease who underwent intestinal resection and were treated with anti-TNF alpha agents postoperatively were assessed retrospectively. Patients were stratified to those with preoperative anti-TNF alpha pharmacodynamic failure and those with no preoperative antiTNF alpha treatment. Results: A total of 53 children were included, 18 with pharmacodynamic failure and 35 controls. Median age at intestinal resection was 14.8 years with 23 (43%) girls. The median time from intestinal resection to anti-TNF alpha initiation was 8 months (interquartile range 4-14 months). At the time of postoperative anti-TNF alpha initiation there were no differences in clinical, laboratory, and anthropometric measures between groups. Similar proportions of patients from both groups were in clinical remission on anti-TNF alpha treatment after 12 months and at the end of follow-up (1.8 years, interquartile range, 1-2.9 years): 89% versus 88.5% and 83% versus 80% for pharmacodynamic failure patients and controls, respectively; P = 0.9. No significant differences were observed at 14 weeks and 12 months of postoperative anti-TNF alpha treatment including endoscopic remission rate and fecal calprotectin. Both groups significantly improved all measures during postoperative anti-TNF alpha treatment. Conclusions: Pediatric patients with Crohn&apos;s disease who failed anti-TNF alpha therapy despite adequate drug levels and underwent intestinal resection can be re-treated with the same agent for postoperative recurrence with high success rate similar to that of anti-TNF alpha naive patients.

Název v anglickém jazyce

Anti-TNF alpha Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure

Popis výsledku anglicky

Background: The outcome of patients with Crohn&apos;s disease who failed anti-tumor necrosis factor alpha (anti-TNF alpha) therapy despite adequate serum drug levels (pharmacodynamic failure) is unclear. We aimed to assess such pediatric patients who underwent intestinal resection and were re-treated with the same anti-TNF alpha agent postoperatively. Methods: Pediatric patients with Crohn&apos;s disease who underwent intestinal resection and were treated with anti-TNF alpha agents postoperatively were assessed retrospectively. Patients were stratified to those with preoperative anti-TNF alpha pharmacodynamic failure and those with no preoperative antiTNF alpha treatment. Results: A total of 53 children were included, 18 with pharmacodynamic failure and 35 controls. Median age at intestinal resection was 14.8 years with 23 (43%) girls. The median time from intestinal resection to anti-TNF alpha initiation was 8 months (interquartile range 4-14 months). At the time of postoperative anti-TNF alpha initiation there were no differences in clinical, laboratory, and anthropometric measures between groups. Similar proportions of patients from both groups were in clinical remission on anti-TNF alpha treatment after 12 months and at the end of follow-up (1.8 years, interquartile range, 1-2.9 years): 89% versus 88.5% and 83% versus 80% for pharmacodynamic failure patients and controls, respectively; P = 0.9. No significant differences were observed at 14 weeks and 12 months of postoperative anti-TNF alpha treatment including endoscopic remission rate and fecal calprotectin. Both groups significantly improved all measures during postoperative anti-TNF alpha treatment. Conclusions: Pediatric patients with Crohn&apos;s disease who failed anti-TNF alpha therapy despite adequate drug levels and underwent intestinal resection can be re-treated with the same agent for postoperative recurrence with high success rate similar to that of anti-TNF alpha naive patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Inflammatory Bowel Diseases

ISSN

1078-0998

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

791-797

Kód UT WoS článku

000404532300022

EID výsledku v databázi Scopus

2-s2.0-85019856531